NEUROLIGN TECHNOLOGIES INC. TO PRESENT AT BIOTECH SHOWCASE™ 2020 IN SAN FRANCISCO
Neurolign presenting company overview at BioTech Showcase
Toronto, ON, January 8, 2020 – Neurolign Technologies Inc. (“Neurolign”) has scheduled company presentations at Biotech Showcase™ 2020, to be held January 13–15, a critical event for healthcare innovation and investment at the Hilton San Francisco Union Square.
Neurolign will be presenting at the Biotech Showcase on:
Date: Monday January 13, 2020
Venue: Hilton San Francisco Union Square
Address: 333 O’Farrell Street, San Francisco, CA 94102
Room: Franciscan C (Ballroom Level)
And at the Digital Medicine and Medtech Showcase
Date: Wednesday January 15, 2020
Venue: Parc 55 San Francisco - Union Square
Address: 55 Cyril Magnin Street, San Francisco, CA 94102
Room: Balboa (4th Floor)
Neurolign is a privately held neuroscience diagnostic and therapeutics company focused initially on the diagnosis and treatment of mTBI and concussion. Neurolign has recently acquired an eye-tracking diagnostic platform and are actively working on the development of therapeutic products to treat the symptoms of concussion and digital technologies to support treatment. This platform approach will be subsequently leveraged to support other neurological conditions in the future. Neurolign's founder is Eugene Melnyk, the creator of multiple healthcare companies, including Biovail Corporation (acquired by Bausch Health), and the current owner of the Ottawa Senators NHL Hockey Club.
“We are thrilled to showcase Neurolign at both the Biotech Showcase and Digital Medicine and Medtech Showcase to raise awareness of our company among investors and potential partners but also to further entrench our company in the ecosystem of innovative health care companies advancing health for the public as well as health care outcomes for patients” noted Derek Clark, Neurolign’s Chief Operating Officer.
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.
“We are delighted that Neurolign will be presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”
ABOUT BIOTECH SHOWCASE
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its 12th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.
Neurolign Technologies is dedicated to creating a quantum shift in the diagnosis and treatment of neurodegenerative disease. Through the unique combination of high precision medical devices as well as specialty formulations and drug delivery technologies, Neurolign is creating a revolutionary approach to the assessment and treatment of brain injury and disease. Whether you are a patient or a medical professional, our world-class diagnostics and novel therapeutics can support the pursuit of optimal brain health. Our portfolio and services offer an evidence-based, holistic ability to deliver more accurate and timely diagnostic and treatment options. Additional information on Neurolign is available at www.neurolign.com.
Derek Clark, Chief Operating Officer, Neurolign Technologies Inc.,